Genes and diabetic retinopathy

Indian Journal of Ophthalmology

Volumn 50, Issue 1, 2002, Pages 5-11

  Radha, Venkatesan ^a   Rema, Mohan ^a   Mohan, Viswanathan ^a  

^a MADRAS DIABETES RESEARCH FOUNDATION   (India)

Author keywords

Candidate genes; Diabetic retinopathy; Genetics; India

Indexed keywords

ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; ALDEHYDE REDUCTASE; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL CELL GROWTH FACTOR; HLA ANTIGEN; IMMUNOGLOBULIN RECEPTOR; LYMPHOKINE; NITRIC OXIDE SYNTHASE; VASCULOTROPIN; VASCULOTROPIN A;

DIABETIC RETINOPATHY; GENE; GENETICS; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

ALDEHYDE REDUCTASE; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; ENDOTHELIAL GROWTH FACTORS; GENES; HLA ANTIGENS; HUMANS; LYMPHOKINES; NITRIC OXIDE SYNTHASE; PEPTIDYL-DIPEPTIDASE A; RECEPTORS, IMMUNOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036490084     PISSN: 03014738     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Taylor HR, Keefee JF. World blindness: A 21st century perspective. Br J Ophthalmol 2001;85:261-66.
2. Cahill G, Etzweiler L, Freinkel N. Control and diabetes. N Engl J Med 1976;294:1004-5.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive insulin treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
4. Pyke DA, Tattersall RB. Diabetic retinopathy in identical twins. Diabetes 1973;22:613-18.
5. DCCT Research Group. Clustering of long term complications in families with diabetes in the Diabetes Control and Complications Trial. Diabetes 1997;46:1829-39.
6. Alcolado J. Genetics of diabetic complications. Lancet 1998;351:230-31.
7. Nathan DM. Long term complications of diabetes mellitus. N Engl J Med 1993;328:1676-85.
8. DCCT Research Group. The absence of glycemic threshold for the development of long term complications. The perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45:1289-98.
9. UK Prospective Diabetes Study (UKPDS) group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998;352:1-18.
10. Larkins RG, Dunlop ME. The link between hyperglycemia and diabetic nephropathy. Diabetologia 1992;35:499-504.
11. Mohman TC, Nishimura C, Robinson WG Jr. Aldose reductase and polyol in cultured pericytes of human retinal capillaries. Exp Eye Research 1989;48:55-60.
12. Mugregor LC, Matschinsky FM. Altered retinal metabolism in diabetes II measurement of sodium potassium ATPase and total sodium and potassium in individual retinal layers. J Bio Chem 1986;26:4052-58.
13. Engerman RL. Pathogenesis of diabetic retinopathy. Diabetes 1989;38:1203-06.
14. Graham A, Meath P, Morten JEM, Markham AF. The human aldose reductase gene maps to chromosome 7q3S. Human Genet 1991;86:509-14.
15. Hamada Y, Kitoh R, Raskin P. Increased erythrocyte aldose reductase activity in Type 1 diabetic patients. Diabetic Medicine 1991;8:226-31.
16. Hamada Y, Kitoh R, Raskin P. Association of erythrocyte aldose reductase activity with diabetic complications in Type 1 diabetes mellitus. Diabetic Medicine 1993;10:33-38.
17. Nishimura C, Saito T, Ito T, Omori Y, Tamimoto T. High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients. Diabetologia 1994;37:328-30.
18. Ko BC, Lam KS, Wat NM, Chung SS. An (A-C)n dinucleotide repeat polymorphic marker at the 5′ end of the aldose reductase gene is associated with early onset diabetic retinopathy in NIDDM patients. Diabetes 1995;44:727-32.
19. Patel A, Hibberd ML, Millward BA, Demaine AG. Chromosome 7q35 and susceptibility to diabetic microvascular complications. J Diab Complications 1996;10:62-67.
20. Stehouwer CDA, Lambert J, Donker AJM, van Hinsberg VWM. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997;34;55-68.
21. Chakravarthy U, Hayes RG, Stitt AW, McAuley E, Archer DB. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 1998;47;945-52.
22. Warpeha KM, Xu W, Liu L, Charles IG, Patterson CC, AH-Fat F, et al. Genotyping and functional analysis of a polymorphic (CCTTT) in repeat of NOS2A in diabetic retinopathy. Faseb J 1999;13:1825-32.
23. Browlee M, Grami A, Vlassara H. Advanced glycated end-products in tissue and the biochemical basis of diabetic complications. New Eng J Med 1988;318:1315-21.
24. Brownlee M. Glycation and diabetic complications. Diabetes 1994;43:836-41.
25. Neeper M, Schmidt AM, Brett J, Yans D, Wang F, Pan YCE, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992;267:14998-5004.
26. Liu L, Xiang K. RAGE Gly 82 Ser Polymorphism in diabetic microangiopathy. Diabetes Care 1999;22:646.
27. Hudson BI, Stickland MH, Grant PJ. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: Prevalence in Type 2 diabetes and ethnic groups. Diabetes 1998;47:1155-57.
28. Vlassara H. Diabetes and advanced glycation end products. In: Johnstone MT, Veves A, editors. Diabetes and Cardiovascular Disease. New Jersey: Humana Press Inc. 2001. pp 81-102.
29. Agardh A, Gour LK, Agardh F, Landin-Olsson ML, Agardh C, A Lernmark, et al. HLA-DQ B1 0201 / 0302 is associated with severe retinopathy in patients with IDDM. Diabetologia 1996;39:1313-17.
30. Mijovic C, Fletcher J, Bradwell AR, Harvey T, Barnett AH. Relation of gene expression (allotypes) of the fourth component of complement to insulin dependent diabetes and its microangiographic complications. Br Med J 1985;291:9-10.
31. Lhotta K, Auingen M, Kronenberg F, Irsingler K, Konig P. Polymorphism of complement C4 and susceptibility to IDDM and microvascular complications. Diabetes Care 1996;19:53-55.
32. Hawrami K, Mohan R, Mohan V, Hitman GA. A genetic study of retinopathy in south Indian Type 2 diabetic patients. Diabetologia 1991;34:441-44.
33. Hawrami K, Hitman GA, Rema M, Snehalatha C, Viswanathan M, Ramachandran A, Mohan V. An association in non-insulin dependent diabetes mellitus subjects susceptibility to retinopathy and tumour necrosis factor polymorphism. Human Immunology 1996;46:49-54.
34. Erelas EG. Angiotensin I - converting enzyme and the changes in our concepts through the years. Hypertension 1990;16:363-70.
35. Mubert C, Moust AM, Corrol P, Soubrier F. Structure of the angiotensin-I converting enzyme gene. JBC 1991;266:15377-83.
36. Rigat B, Hubert C, Alhene C, Gelas F, Combien F, Corval P, et al. An insertion / deletion polymorphism in the angiotensin-I converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-46.
37. Rigat B, Hubert C, Corrol P, Sonbrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidel1). Nucleic Acids Research 1992;20:1433.
38. Nagi DK, Mansfield MW, Stickland BM, Grant PJ. Angiotensin converting enzyme (ACE) insertion/ deletion (I/D) polymorphism and diabetic retinopathy in subjects with IDDM and NIDDM. Diabetic Medicine 1993;12:997-1001.
39. Doi Y, Yoshizumi H, Yoshinari M, Lino K, Yamamoto M, Ichikawa K, et al. Association between a polymorphism in the angiotensin converting enzyme gene and microvascular complications in Japanese patients with NIDDM. Diabetologia 1996;39:97-02.
40. Tiret L, Rigat B, Visvikis S, Breda C, Carrol P, Cambien F, et al. Evidence from combined segregation and linkage analysis that a variant of angiotensin-1 converting enzyme (ACE) gene control plasma ACE levels. Am J Hum Genet 1992;S1:197-205.
41. Barley J, Blackwood A, Carter ND, Crews DE, Cruickshank JK, Jefferey S, et al. Angiotensin converting enzyme insertion / deletion polymorphism association with ethnic origin. J Hypertens 1994;12:955-57.
42. Fujisama T, Ikegam H, Kawaguchi Y, Hamada Y, Ueda H, Shintani M, et al. Meta- analysis of association of insertion / deletion polymorphism of angiotensin 1 converting enzyme with diabetic nephropathy and retinopathy. Diabetologia 1998;41:47-53.
43. Migdalis IN, Iliopoulou V, Kalageropolalu K, Samartzis M. Elevated serum levels of angiotensin converting enzyme in patients with diabetic retinopathy. South Med J 1990;83:425-27.
44. Feman SS, Mericle RA, Reed GW, May JM, Workman RJ. Serum angiotensin converting enzyme in diabetic patients. Am J Med Sci 1993;305:280-84.
45. Rabensteiner D, Abrahamian M, Irsingler K, Hermann KM, Keiner HP, Mayer G, et al. ACE gene polymorphism and proliferative retinopathy in Type 1 diabetic patients. Diabetes Care 1999;22:9.
46. Matsumoto A, Iwashima Y, Abiko A, Morikawa A, Sekiguchi M, Eto M, et al. Detection of the association between a deletion polymorphism in the gene encoding angiotensin I converting enzyme and advanced diabetic retinopathy. Diab Res Clin Pract 2000;50:195-202.
47. Duh Elia, Aiella LP. Vascular Endothelial growth factors and diabetes. Diabetes 1999;48:1899-906.
48. Gilbert RE, Vranes D, Berka JL, Kelly DL, Cox A, Stacker SA, et al. Vascular endothelial growth factor and its receptor in control and diabetic rat eyes. Laboratory Investigations 1998.
49. Tischer E, Mitchell R, Harlmian T, Silva M, Gospodarowicz D, Fiddes JC, et al. The human gene for vascular endothelial growth factor. Multiple protein are encoded through alternative exon splicing. J Biol Chem 1991;266:11947-54.
50. Barleon B, Siemester G, Marting-Barong, Weindel K, Herdzog C, Marme D, et al. Vascular endothelial growth factor up-regulates its receptor like tyrosine kinase 1 (flt-1) and a soluble variant of flt.1 in human vascular endothelial cells. Cancer Res 1997;57:5421-25.